Search

Your search keyword '"Intlekofer, Andrew M"' showing total 40 results
Start Over Author "Intlekofer, Andrew M" Journal blood
40 results on '"Intlekofer, Andrew M"'

1. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting

Author

He, Jie, Abdel-Wahab, Omar, Nahas, Michelle K., Wang, Kai, Rampal, Raajit K., Intlekofer, Andrew M., Patel, Jay, Krivstov, Andrei, Frampton, Garrett M., Young, Lauren E., Zhong, Shan, Bailey, Mark, White, Jared R., Roels, Steven, Deffenbaugh, Jason, Fichtenholtz, Alex, Brennan, Timothy, Rosenzweig, Mark, Pelak, Kimberly, Knapp, Kristina M., Brennan, Kristina W., Donahue, Amy L., Young, Geneva, Garcia, Lazaro, Beckstrom, Selmira T., Zhao, Mandy, White, Emily, Banning, Vera, Buell, Jamie, Iwanik, Kiel, Ross, Jeffrey S., Morosini, Deborah, Younes, Anas, Hanash, Alan M., Paietta, Elisabeth, Roberts, Kathryn, Mullighan, Charles, Dogan, Ahmet, Armstrong, Scott A., Mughal, Tariq, Vergilio, Jo-Anne, Labrecque, Elaine, Erlich, Rachel, Vietz, Christine, Yelensky, Roman, Stephens, Philip J., Miller, Vincent A., van den Brink, Marcel R.M., Otto, Geoff A., Lipson, Doron, and Levine, Ross L.

Published
2016
Full Text
View/download PDF

2. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Wills, Beatriz, primary, Ganesan, Nivetha, additional, Shah, Gunjan L., additional, Wong, Phillip, additional, Argyropoulos, Kimon V., additional, Sen, Filiz, additional, Dogan, Ahmet, additional, Straus, David J., additional, Noy, Ariela, additional, Kumar, Anita, additional, Schoder, Heiko, additional, Michaud, Laure, additional, Palomba, Maria Lia, additional, Falchi, Lorenzo, additional, Lahoud, Oscar B, additional, Hamlin, Paul A., additional, Yahalom, Joachim, additional, Johnson, William T., additional, Zelenetz, Andrew D., additional, Intlekofer, Andrew M., additional, Owens, Colette, additional, Batlevi, Connie Lee, additional, Hamilton, Audrey, additional, Caron, Philip C, additional, Horwitz, Steven M., additional, Galasso, Natasha, additional, Hancock, Helen, additional, Davey, Theresa, additional, Santarosa, Alayna, additional, Perez, Leslie, additional, Capadona, Charisse, additional, Munayirji, Brittney, additional, Matasar, Matthew J., additional, Pongas, Georgios, additional, Casper, Ellie, additional, Salles, Gilles, additional, Moskowitz, Craig H., additional, Vardhana, Santosha, additional, and Moskowitz, Alison J., additional

Published
2022
Full Text
View/download PDF

3. Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Author

Batlevi, Connie Lee, primary, Drill, Esther, additional, Okwali, Michelle, additional, Ptashkin, Ryan, additional, Caron, Philip C, additional, Epstein-Peterson, Zachary D., additional, Falchi, Lorenzo, additional, Hamilton, Audrey, additional, Hamlin, Paul A., additional, Horwitz, Steven M., additional, Intlekofer, Andrew M., additional, Johnson, William T., additional, Khan, Niloufer, additional, Kumar, Anita, additional, Lue, Jennifer Kimberly, additional, Matasar, Matthew J., additional, Moskowitz, Alison J., additional, Noy, Ariela, additional, Owens, Colette, additional, Palomba, Maria Lia, additional, Straus, David J., additional, Vardhana, Santosha, additional, Zelenetz, Andrew D., additional, Arcila, Maria E., additional, Dogan, Ahmet, additional, Seshan, Venkatraman, additional, Salles, Gilles, additional, Zehir, Ahmet, additional, and Younes, Anas, additional

Published
2022
Full Text
View/download PDF

4. Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Author

Stuver, Robert, primary, Drill, Esther, additional, Qualls, David, additional, Okwali, Michelle, additional, Batlevi, Connie Lee, additional, Caron, Philip C, additional, Epstein-Peterson, Zachary D., additional, Falchi, Lorenzo, additional, Hamilton, Audrey, additional, Hamlin, Paul A., additional, Horwitz, Steven M., additional, Intlekofer, Andrew M., additional, Johnson, William T., additional, Khan, Niloufer, additional, Lahoud, Oscar B, additional, Lue, Jennifer Kimberly, additional, Matasar, Matthew J., additional, Moskowitz, Alison J., additional, Noy, Ariela, additional, Palomba, M.Lia, additional, Vardhana, Santosha, additional, Zelenetz, Andrew D., additional, Salles, Gilles, additional, and Straus, David J., additional

Published
2022
Full Text
View/download PDF

5. Distinct Patterns of CD4+ and CD8+ T-Cell Clonal Expansion Enable Broad Clinical Responses to Pembrolizumab + GVD in Patients with Relapsed Hodgkin Lymphoma

Author

Wills, Beatriz, Rahman, Jahan, Ganesan, Nivetha, Shah, Gunjan L., Noy, Ariela, Schoder, Heiko, Yahalom, Joachim, Kumar, Anita, Falchi, Lorenzo, Hamlin, Paul A., Palomba, Maria Lia, Johnson, William, Intlekofer, Andrew M., Caron, Philip, Davey, Theresa, Hancock, Helen, Galasso, Natasha, Munayirji, Brittney, Hui Lin, Ya, Santarosa, Alayna, Casper, Ellie, Pongas, Georgio, Zelenetz, Andrew D., Moskowitz, Craig H., Salles, Gilles, Vardhana, Santosha A, and Moskowitz, Alison

Published
2023
Full Text
View/download PDF

6. Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab

Author

Shahid, Zainab, Okwali, Michelle, Joseph, Ashlee, Seo, Susan K., Lue, Jennifer Kimberly, Boardman, Alexander P., Caron, Philip, David, Kevin A., Epstein-Peterson, Zachary D., Ghione, Paola, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Moskowitz, Alison, Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Salles, Gilles, and Falchi, Lorenzo

Published
2023
Full Text
View/download PDF

7. Predicting Toxicities in Older Adults with Non-Hodgkin Lymphoma (NHL) Receiving Systemic Chemotherapy: A Prospective Geriatric Assessment (GA) Study

Author

Torka, Pallawi, Drill, Esther, Ganesan, Nivetha, Oliveros, Mayan, Boardman, Alexander P., Caron, Philip, David, Kevin A., Epstein-Peterson, Zachary D., Falchi, Lorenzo, Ghione, Paola, Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Lue, Jennifer Kimberly, Moskowitz, Alison, Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Stuver, Robert, Vardhana, Santosha A, Zelenetz, Andrew D., Salles, Gilles, and Hamlin, Paul A.

Published
2023
Full Text
View/download PDF

8. Clinical Characteristics and Outcomes of Limited Stage High Grade B-Cell Lymphoma with MYC/BCL2 and/or BCL6 Rearrangements: A Single Center Experience

Author

Lue, Jennifer Kimberly, Luttwak, Efrat, Caron, Philip, Boardman, Alexander P., David, Kevin A., Rivas-Delgado, Alfredo, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Ghione, Paola, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Moskowitz, Alison, Noy, Ariela, Palomba, Maria Lia, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Zhang, Yanming, Galera, Pallavi, Dogan, Ahmet, Aypar, Umut, and Salles, Gilles

Published
2023
Full Text
View/download PDF

9. Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma -Real World Experience

Author

Luttwak, Efrat, Ganesan, Nivetha, Boardman, Alexander P., Caron, Philip, David, Kevin A., Rivas-Delgado, Alfredo, Falchi, Lorenzo, Ghione, Paola, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Lue, Jennifer Kimberly, Noy, Ariela, Palomba, Maria Lia, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Salles, Gilles, and Moskowitz, Alison

Published
2023
Full Text
View/download PDF

10. Impact of Early Histological Transformation on Survival in Patients with Follicular Lymphoma

Author

Luttwak, Efrat, Qiu, Annie, Okwali, Michelle, Rivas-Delgado, Alfredo, Isgor, Irem, Boardman, Alexander P., Caron, Philip, David, Kevin A., Falchi, Lorenzo, Ghione, Paola, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Lue, Jennifer Kimberly, Moskowitz, Alison, Noy, Ariela, Galera, Pallavi, Palomba, M. Lia, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Schoder, Heiko, Yahalom, Joachim, Dogan, Ahmet, and Salles, Gilles

Published
2023
Full Text
View/download PDF

11. A Phase 1b Multi-Center Study of the FLT3 Inhibitor Gilteritinib in Combination with the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring FLT3/IDH1 or FLT3/IDH2 Mutations

Author

Stein, Eytan M., Derkach, Andriy, Melamed, Gabrielle, Block, Alana, Kim, Janet, Georgieva, Gergana, Thompson, Vanessa, Levine, Ross L, Intlekofer, Andrew M., Abdel-Wahab, Omar, and Tallman, Martin S.

Published
2023
Full Text
View/download PDF

12. Responses and Outcomes after Second-Line Therapy in Transplant-Eligible Patients with DLBCL Relapse over 1 Year after First-Line Therapy

Author

Qualls, David A, Shah, Gunjan L., Shouval, Roni, Caron, Philip, David, Kevin A., Falchi, Lorenzo, Ghione, Paola, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Lahoud, Oscar Boutros, Lue, Jennifer Kimberly, Moskowitz, Alison, Noy, Ariela, Palomba, Maria Lia, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Okwali, Michelle, Dahi, Parastoo Bahrami, Scordo, Michael, Lin, Richard J., Perales, Miguel-Angel, and Salles, Gilles

Published
2023
Full Text
View/download PDF

13. Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Author

Cassanello, Giulio, Rivas-Delgado, Alfredo, Luna De Abia, Alejandro, Corona, Magdalena, Luttwak, Efrat, Okwali, Michelle, Isgor, Irem, Galera, Pallavi, Boardman, Alexander P., Caron, Philip, David, Kevin A., Epstein-Peterson, Zachary D., Ghione, Paola, Hamlin, Paul A., Lue, Jennifer Kimberly, Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Moskowitz, Alison, Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Salles, Gilles, and Falchi, Lorenzo

Published
2023
Full Text
View/download PDF

14. Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era

Author

Robin, Edith Tama, Drill, Esther, Batlevi, Connie Lee, Caron, Philip, Falchi, Lorenzo, Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Joffe, Erel, Kumar, Anita, Matasar, Matthew J, Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Rodriguez-Rivera, Ildefonso, Straus, David J., Vardhana, Santosha, von Keudell, Gottfried R., Zelenetz, Andrew D, Moskowitz, Craig H., and Moskowitz, Alison J.

Published
2020
Full Text
View/download PDF

15. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Moskowitz, Alison J., primary, Shah, Gunjan, additional, Schöder, Heiko, additional, Ganesan, Nivetha, additional, Hancock, Helen, additional, Davey, Theresa, additional, Sohail, Samia, additional, Santarosa, Alayna, additional, Pomerantz, Lauren, additional, Jarjies, Christine, additional, Galasso, Natasha, additional, Neuman, Rachel, additional, Kumar, Anita, additional, Lahoud, Oscar B, additional, Batlevi, Connie Lee, additional, Hamlin, Paul A., additional, Straus, David J., additional, Rodriguez-Rivera, Ildefonso, additional, Owens, Colette, additional, Caron, Philip, additional, Intlekofer, Andrew M., additional, Hamilton, Audrey, additional, Horwitz, Steven M., additional, Falchi, Lorenzo, additional, Joffe, Erel, additional, Palomba, Maria Lia, additional, Noy, Ariela, additional, Matasar, Matthew J, additional, Pongas, Georgios, additional, Vardhana, Santosha, additional, von Keudell, Gottfried R., additional, Yahalom, Joachim, additional, Zelenetz, Andrew D, additional, and Moskowitz, Craig H., additional

Published
2020
Full Text
View/download PDF

16. High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma

Author

Moskowitz, Alison J., primary, Shah, Gunjan L., additional, Schoder, Heiko, additional, Hancock, Helen, additional, Davey, Theresa, additional, Joong, Christopher, additional, Pomerantz, Lauren, additional, Jarjies, Christine, additional, Kumar, Anita, additional, Lahoud, Oscar B, additional, Batlevi, Connie Lee, additional, Hamlin, Paul A., additional, Straus, David J., additional, Rodriguez-Rivera, Ildefonso, additional, Owens, Colette, additional, Caron, Philip, additional, Colbourn, Donald Steven, additional, Intlekofer, Andrew M., additional, Hamilton, Audrey, additional, Horwitz, Steven M., additional, Joffe, Erel, additional, Palomba, M. Lia, additional, Noy, Ariela, additional, Matasar, Matthew J, additional, Vardhana, Santosha, additional, von Keudell, Gottfried R., additional, Yahalom, Joachim, additional, Younes, Anas, additional, Zelenetz, Andrew D., additional, and Moskowitz, Craig H., additional

Published
2019
Full Text
View/download PDF

17. Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Author

Schade, Jake R., primary, Kim, Charles, additional, Drill, Esther, additional, Qiu, Annie, additional, Batlevi, Connie Lee, additional, Caron, Philip, additional, Colbourn, Donald Steven, additional, Hamilton, Audrey, additional, Hamlin, Paul A., additional, Horwitz, Steven M., additional, Intlekofer, Andrew M., additional, Joffe, Erel, additional, von Keudell, Gottfried R., additional, Kumar, Anita, additional, Noy, Ariela, additional, Okwali, Michelle, additional, Owens, Colette, additional, Palomba, M. Lia, additional, Rodriguez-Rivera, Ildefonso, additional, Sauter, Craig S., additional, Schoder, Heiko, additional, Straus, David J., additional, Vardhana, Santosha, additional, Younes, Anas, additional, Zelenetz, Andrew D., additional, and Matasar, Matthew J, additional

Published
2019
Full Text
View/download PDF

18. Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era

Author

Batlevi, Connie, primary, Alperovich, Anna, additional, Smith, Katy, additional, Ying, Zhitao, additional, Soumerai, Jacob D, additional, Copeland, Amanda R, additional, Joffe, Erel, additional, Caron, Philip, additional, Drullinsky, Pamela, additional, Gerecitano, John F, additional, Hamilton, Audrey, additional, Hamlin, Paul A, additional, Horwitz, Steven M, additional, Intlekofer, Andrew M, additional, Kumar, Anita, additional, Matasar, Matthew J., additional, Moskowitz, Alison J., additional, Moskowitz, Craig H, additional, Noy, Ariela, additional, Palomba, Maria Lia, additional, Portlock, Carol S, additional, Sauter, Craig S, additional, Straus, David J, additional, Zelenetz, Andrew D., additional, Ni, Ai, additional, Seshan, Venkatraman E, additional, and Younes, Anas, additional

Published
2016
Full Text
View/download PDF

19. Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed

Author

Soumerai, Jacob D, primary, Bantilan, Kurt S, additional, Ni, Ai, additional, Batlevi, Connie, additional, Alperovich, Anna, additional, Smith, Katy, additional, Ying, Zhitao, additional, Copeland, Amanda R, additional, Matasar, Matthew J., additional, Straus, David J, additional, Gerecitano, John F, additional, Hamlin, Paul A, additional, Horwitz, Steven M, additional, Portlock, Carol S, additional, Palomba, Maria Lia, additional, Moskowitz, Craig H, additional, Moskowitz, Alison J, additional, Noy, Ariela, additional, Sauter, Craig S, additional, Kumar, Anita, additional, Intlekofer, Andrew M, additional, Caron, Philip, additional, Drullinsky, Pamela, additional, Younes, Anas, additional, and Zelenetz, Andrew D, additional

Published
2016
Full Text
View/download PDF

20. Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era

Author

Alperovich, Anna, primary, Batlevi, Connie, additional, Smith, Katy, additional, Ying, Zhitao, additional, Soumerai, Jacob D, additional, Copeland, Amanda R, additional, Joffe, Erel, additional, Caron, Philip, additional, Drullinsky, Pamela, additional, Gerecitano, John F, additional, Hamilton, Audrey, additional, Hamlin, Paul A, additional, Horwitz, Steven M, additional, Intlekofer, Andrew M, additional, Kumar, Anita, additional, Matasar, Matthew J, additional, Moskowitz, Alison J., additional, Moskowitz, Craig H, additional, Noy, Ariela, additional, Palomba, Maria Lia, additional, Portlock, Carol S, additional, Sauter, Craig S, additional, Straus, David J, additional, Zelenetz, Andrew D., additional, Ni, Ai, additional, Seshan, Venkatraman E, additional, and Younes, Anas, additional

Published
2016
Full Text
View/download PDF

21. Clinical Characteristics and Outcomes of Limited Stage High Grade B-Cell Lymphoma with MYC/BCL2and/or BCL6Rearrangements: A Single Center Experience

Author

Lue, Jennifer Kimberly, Luttwak, Efrat, Caron, Philip, Boardman, Alexander P., David, Kevin A., Rivas-Delgado, Alfredo, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Ghione, Paola, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Moskowitz, Alison, Noy, Ariela, Palomba, Maria Lia, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Zhang, Yanming, Galera, Pallavi, Dogan, Ahmet, Aypar, Umut, and Salles, Gilles

Abstract

Introduction:High grade B-cell lymphoma with MYC, BCL2and/or BCL6rearrangements (HGBCL MYC/BCL2and/or BCL6-R)is a group of aggressive lymphomas associated with poor outcomes when treated with R-CHOP. Most HGBCL present in advanced stage and have a high risk for CNS relapse. MYCpartner (Immunoglobulin (IG) vs. Non-IG) status has been correlated with clinical outcomes. Recent data suggests that MYC/BCL6translocations may not portend the same inferior outcomes as MYC/BCL2-R and that limited stage HGBCL MYC/BCL2-R may have similar PFS and OS when treated with intensive chemotherapy vs. R-CHOP. In this study, we aimed to build upon the paucity of data available by describing the clinical characteristics of limited stage HGBCL including the risk of CNS relapse, and the role of MYCpartner on clinical outcome.

Published
2023
Full Text
View/download PDF

22. Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management

Author

Morley, Samantha, primary, He, Jie, additional, Intlekofer, Andrew M., additional, Bailey, Mark, additional, Nahas, Michelle, additional, Lipson, Doron, additional, Yelensky, Roman, additional, Ross, Jeffrey, additional, Ali, Siraj, additional, Erlich, Rachel, additional, Stephens, Phil, additional, Miller, Vincent A., additional, Vergilio, Jo-Anne, additional, and Mughal, Tariq I, additional

Published
2015
Full Text
View/download PDF

23. Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma

Author

Batlevi, Connie, primary, Rapaport, Franck, additional, Wang, Lu, additional, Intlekofer, Andrew M., additional, Copeland, Amanda R., additional, Jungbluth, Achim A, additional, Reiner, Anne, additional, Pichardo, Janine D., additional, Gallagher, Meighan, additional, Bouvier, Nancy, additional, Socci, Nicholas D., additional, Criscuolo, Frederick, additional, Schultz, Nikolaus, additional, Arcila, Maria, additional, Berger, Michael, additional, Zelenetz, Andrew D, additional, Seshan, Venkatraman E, additional, Dogan, Ahmet, additional, and Younes, Anas, additional

Published
2015
Full Text
View/download PDF

24. Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay

Author

Batlevi, Connie, primary, Rapaport, Franck, additional, Intlekofer, Andrew M., additional, Reiner, Anne, additional, Moskowitz, Craig H, additional, Horwitz, Steven M, additional, Zelenetz, Andrew D, additional, Palomba, Lia, additional, Moskowitz, Alison J, additional, Gerecitano, John F., additional, Hamlin, Paul A, additional, Copeland, Amanda R., additional, Matasar, Matthew J, additional, Sauter, Craig S., additional, Kumar, Anita, additional, Noy, Ariela, additional, Straus, David J., additional, Portlock, Carol S., additional, Criscuolo, Frederick, additional, He, Jie, additional, Royston, Daniel, additional, Balasubramanian, Sohail, additional, Reznikovskaya, Yekaterina, additional, Pichardo, Janine D., additional, Stephens, Phil, additional, Miller, Vincent, additional, Levine, Ross L., additional, Seshan, Venkatraman, additional, Dogan, Ahmet, additional, and Younes, Anas, additional

Published
2015
Full Text
View/download PDF

25. Comprehensive Genomic Profiling (CGP) Informs Molecular Diagnosis, Prognosis, and Therapeutic Decision-Making for Patients with Angioimmunoblastic T-Cell Lymphoma (AITL)

Author

Morley, Samantha, He, Jie, Intlekofer, Andrew M, Bailey, Mark, Nahas, Michelle, Heilmann, Andreas, Chudnovsky, Yakov, Fabrizio, David, Ali, Siraj M, Lipson, Doron, Stephens, Philip J, Ross, Jeffrey S, Miller, Vincent A, Severson, Eric A, Vergilio, Jo-Anne, Abdel-Wahab, Omar, Erlich, Rachel, and Mughal, Tariq I

Published
2017
Full Text
View/download PDF

26. Genomic Characteristics Clinical Phenotype and Disease Course of TP53 Mutated Diffuse Large B Cell Lymphoma at Diagnosis and Relapse

Author

Joffe, Erel, Batlevi, Connie L., Intlekofer, Andrew M, Zelenetz, Andrew D., Moskowitz, Craig H., Palomba, Maria L., Noy, Ariela, Straus, David J., Portlock, Carol S., Gerecitano, John, Horwitz, Steven M., Moskowitz, Alison J., Hamlin, Paul A., Matasar, Matthew J., Kumar, Anita, He, Jie, Miller, Vincent A, Rapaport, Franck, Papaemmanuil, Elli, Dogan, Ahmet, and Younes, Anas

Published
2017
Full Text
View/download PDF

27. Impact of PET Staging of Follicular Lymphoma on Treatment Outcomes and Prognosis

Author

Alperovich, Anna, Batlevi, Connie L., Intlekofer, Andrew M, Moskowitz, Craig H., Horwitz, Steven M., Zelenetz, Andrew D., Palomba, Maria Lia, Moskowitz, Alison J., Gerecitano, John, Hamlin, Paul A., Matasar, Matthew J., Sauter, Craig S., Kumar, Anita, Noy, Ariela, Straus, David J., Portlock, Carol S., Hamilton, Audrey, Drullinsky, Pamela, Caron, Philip, Ni, Ai, Seshan, Venkatraman, and Younes, Anas

Published
2017
Full Text
View/download PDF

28. Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis

Author

Yoshimi, Akihide, Lin, Kuan-Ting, Wiseman, Daniel, Intlekofer, Andrew M, Wang, Bo, Pastore, Alessandro, Rahman, Mohammad, Lee, Stanley Chun-Wei, Liu, Bo, Micol, Jean-Baptiste, De Botton, Stephane, Penard-Lacronique, Virginie, Shih, Alan H., Stein, Eytan M., Durham, Benjamin H, Inoue, Daichi, Zhang, Xiao Jing, Albrecht, Todd, Chung, Young Rock, Peng, Shouyong, Buonamici, Silvia, Palacino, James, Smith, Peter, Thompson, Craig B., Levine, Ross L., Wagner, Eric, Krainer, Adrian R., and Abdel-Wahab, Omar

Published
2017
Full Text
View/download PDF

29. Generation and Application of T-Cell Lymphoma Patient Derived Tumor Xenograft Models

Author

Fiore, Danilo, Wang, Xujun, Khodos, Inna, Di Giacomo, Filomena, Gaudiano, Marcello, Phillip, Jude M, Wang, Rui, Yang, Zhiwei, Ginsberg, Michael, Intlekofer, Andrew M, Thompson, Craig B., Aster, Jon C., Ruan, Jia, Ng, Samuel Y., Jacobsen, Eric, Dogan, Ahmet, de Stanchina, Elisa, Mattar, Marissa, Cerchietti, Leandro, Bareja, Rohan, Elemento, Olivier, Tam, Wayne, Weinstock, David M., Rafii, Shahin, Horwitz, Steven M., and Inghirami, Giorgio

Published
2017
Full Text
View/download PDF

30. AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo

Author

Shih, Alan H., primary, Shank, Kaitlyn R, additional, Meydan, Cem, additional, Intlekofer, Andrew M., additional, Ward, Patrick, additional, Thompson, Craig B., additional, Melnick, Ari M, additional, Travins, Jeremy, additional, Straley, Kim, additional, Gliser, Camelia, additional, Yen, Katherine, additional, and Levine, Ross L, additional

Published
2014
Full Text
View/download PDF

31. Clinical Utility of Comprehensive Profiling of Genomic Alterations in Hematologic Malignancies

Author

He, Jie, primary, Bufill, Jose A., additional, Nahas, Michelle K., additional, Wang, Kai, additional, Young, Lauren E, additional, Knapp, Kristina M., additional, Brennan, Kristina W., additional, Donahue, Amy L, additional, Young, Geneva, additional, Ross, Jeffrey S, additional, Morosini, Deborah, additional, van den Brink, Marcel R. M., additional, Abdel-Wahab, Omar, additional, Rampal, Raajit K., additional, Intlekofer, Andrew M., additional, Dogan, Ahmet, additional, Armstrong, Scott, additional, Yelensky, Roman, additional, Otto, Geoff, additional, Lipson, Doron, additional, Stephens, Philip J., additional, Miller, Vincent A., additional, and Levine, Ross L., additional

Published
2014
Full Text
View/download PDF

32. Genomic Profiling Combining DNA and RNA Analysis of 112 Formalin-Fixed Paraffin-Embedded Diffuse Large B Cell Lymphoma Specimens Identifies a High Frequency of Clinically Relevant Genomic Alterations

Author

Intlekofer, Andrew M., primary, Hilden, Patrick, additional, Seshan, Venkatraman E., additional, Copeland, Amanda R., additional, Levine, Ross L., additional, Zelenetz, Andrew D., additional, Teruya-Feldstein, Julie, additional, Dogan, Ahmet, additional, Palomba, Maria Lia, additional, Moskowitz, Craig H., additional, van den Brink, Marcel R. M., additional, Knapp, Kristina M., additional, Pichardo, Janine D., additional, Brennan, Kristina W., additional, Young, Geneva, additional, He, Jie, additional, Nahas, Michelle K., additional, Yelensky, Roman, additional, Otto, Geoff A., additional, Lipson, Doron, additional, Stephens, Philip J., additional, Miller, Vincent A., additional, and Younes, Anas, additional

Published
2014
Full Text
View/download PDF

34. Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform

Author

Intlekofer, Andrew M., primary, Sheshan, Venkatraman E., additional, Levine, Ross L., additional, Zelenetz, Andrew D., additional, Teruya-Feldstein, Julie, additional, Dogan, Ahmet, additional, Palomba, Maria Lia, additional, Moskowitz, Craig H., additional, van den Brink, Marcel R. M., additional, Knapp, Kristina M., additional, Copeland, Amanda R. M., additional, Pichardo, Janine D., additional, Brennan, Kristina W., additional, Young, Geneva, additional, He, Jie, additional, Nahas, Michelle K., additional, Yelensky, Roman, additional, Otto, Geoff A., additional, Lipson, Doron, additional, Stephens, Philip J., additional, Miller, Vincent A., additional, and Younes, Anas, additional

Published
2013
Full Text
View/download PDF

35. Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay

Author

Lipson, Doron, primary, Nahas, Michelle K, additional, Otto, Geoff A., additional, Yelensky, Roman, additional, Abdel-Wahab, Omar, additional, Wang, Kai, additional, He, Jie, additional, Intlekofer, Andrew M., additional, Rampal, Raajit K., additional, Brennan, Timothy A, additional, Knapp, Kristina M., additional, Brennan, Kristina W, additional, Young, Geneva, additional, Donahue, Amy L, additional, Sanford, Eric M, additional, Greenbowe, Joel R, additional, Frampton, Garrett M, additional, Fichtenholtz, Alex, additional, Young, Lauren E, additional, Erlich, Rachel L, additional, Parker, Alex, additional, Klimstra, David, additional, Dogan, Ahmet, additional, Ross, Jeffrey S, additional, Armstrong, Scott A., additional, Stephens, Philip J., additional, van den Brink, Marcel R. M., additional, Miller, Vincent A., additional, and Levine, Ross L., additional

Published
2013
Full Text
View/download PDF

38. Genomic Characteristics Clinical Phenotype and Disease Course of TP53Mutated Diffuse Large B Cell Lymphoma at Diagnosis and Relapse

Author

Joffe, Erel, Batlevi, Connie L., Intlekofer, Andrew M, Zelenetz, Andrew D., Moskowitz, Craig H., Palomba, Maria L., Noy, Ariela, Straus, David J., Portlock, Carol S., Gerecitano, John, Horwitz, Steven M., Moskowitz, Alison J., Hamlin, Paul A., Matasar, Matthew J., Kumar, Anita, He, Jie, Miller, Vincent A, Rapaport, Franck, Papaemmanuil, Elli, Dogan, Ahmet, and Younes, Anas

Abstract

INTRODUCTION

Published
2017
Full Text
View/download PDF

39. Spliceosomal Dysfunction Is a Critical Mediator of IDH2Mutant Leukemogenesis

Author

Yoshimi, Akihide, Lin, Kuan-Ting, Wiseman, Daniel, Intlekofer, Andrew M, Wang, Bo, Pastore, Alessandro, Rahman, Mohammad, Lee, Stanley Chun-Wei, Liu, Bo, Micol, Jean-Baptiste, De Botton, Stephane, Penard-Lacronique, Virginie, Shih, Alan H., Stein, Eytan M., Durham, Benjamin H, Inoue, Daichi, Zhang, Xiao Jing, Albrecht, Todd, Chung, Young Rock, Peng, Shouyong, Buonamici, Silvia, Palacino, James, Smith, Peter, Thompson, Craig B., Levine, Ross L., Wagner, Eric, Krainer, Adrian R., and Abdel-Wahab, Omar

Abstract

Mutations affecting RNA splicing factors are commonly found in leukemias and mutations in SF3B1, SRSF2, and U2AF1impart specific changes to global splicing. We analyzed RNA-seq data from acute myeloid leukemia (AML) patients from The Cancer Genome Atlas (TCGA) to evaluate for spliceosomal alterations characteristic of mutant SRSF2, SF3B1, and U2AF1. Although only 1 patient with an SRSF2mutation was reported in the TCGA AML publication, we identified 19 additional patients to have the characteristic splicing changes of mutant SRSF2. Mutational analysis of the RNA-seq data identified the SRSF2proline 95 hotspot mutation in each of these 19 patients (19/178, 11%), making SRSF2amongst the most commonly mutated genes in the AML TCGA dataset. Interestingly, 47% of SRSF2mutant patients also had a co-existing IDH2mutation (and conversely, 50% of IDH2mutant patients had a co-existing SRSF2mutation). These data are similar to recent observation that SRSF2mutations were the most common accompanying mutation in IDH2mutant myeloid leukemia patients treated on the phase I clinical trial of AG-221.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results